CoChat

Gene Expression–Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial

Published version of a preprint

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

Abstract

Abstract Purpose: Expression-based classifiers to predict pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT) are not routinely used in the clinic. We aimed to build and validate a classifier for pCR after NACT. Patients and Methods: We performed a prospective multicenter study (EXPRESSION) including 114 patients treated with anthracycline/taxane-based NACT. Pretreatment core needle biopsies from 91 patients were used for gene expression analysis and classifier construction, followed by validation in five external cohorts (n = 619). Results: A 20-gene classifier established in the EXPRESSION cohort using a Youden index–based cut-off point predicted pCR in the validation cohorts with an accuracy, AUC, negative predictive value (NPV), positive predictive value, sensitivity, and specificity of 0.811, 0.768, 0.829, 0.587, 0.216, and 0.962, respectively. Alternatively, aiming for a high NPV by defining the cut-off point for classification based on the complete responder with the lowest predicted probability of pCR in the EXPRESSION cohort led to an NPV of 0.960 upon external validation. With this extreme-low cut-off point, a recommendation to not treat with anthracycline/taxane-based NACT would be possible for 121 of 619 unselected patients (19.5%) and 112 of 322 patients with luminal breast cancer (34.8%). The analysis of the molecular subtypes showed that the identification of patients who do not achieve a pCR by the 20-gene classifier was particularly relevant in luminal breast cancer. Conclusions: The novel 20-gene classifier reliably identifies patients who do not achieve a pCR in about one third of luminal breast cancers in both the EXPRESSION and combined validation cohorts.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-20-2662

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 49 references

Cited by

See all 25

Metadata

Authors
Edlund, K., Madjar, K., Lebrecht, A., Aktas, B., Pilch, H., Hoffmann, G., Hofmann, M., Kolberg, H.-C., Boehm, D., Battista, M., Seehase, M., Stewen, K., Gebhard, S., Cadenas, C., Marchan, R., Brenner, W., Hasenburg, A., Koelbl, H., Solbach, C., Gehrmann, M., Tanner, B., Weber, K. E., Loibl, S., Sachinidis, A., Rahnenführer, J., Schmidt, M., & Hengstler, J. G.
Affiliations
  • TU Dortmund University (DE)
  • University Medical Center of the Johannes Gutenberg University Mainz (DE)
  • University Hospital Leipzig (DE)
  • University Hospital Cologne (DE)
  • St. Josefs Hospital (DE)
  • Marienhospital Stuttgart (DE)
  • Marienhospital Bottrop (DE)
  • 9Center of Minimal Invasive Surgery, Senology and Oncology, mic.ma.mainz, Mainz, Germany.
  • University of Vienna (AT)
  • University Hospital Frankfurt (DE)
  • Bayer (Germany) (DE)
  • 13Practice for Gynecological Oncology, Hoen Neuendorf, Germany.
  • German Breast Group (DE)
  • University of Cologne (DE)
Corresponding author
Hengstler, Jan G.
Venue
Clinical Cancer Research
Published
2021-02-04
Volume
27
Issue
8
Pages
2148-2158
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3129134217
Cited by
24
References
50
Citations by year
2026: 7 · 2025: 2 · 2024: 4 · 2023: 4 · 2022: 4 · 2021: 3
FWCI
1.59
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
Funders
Federal Ministry of Education and Research (01GR0816)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
Keywords
early breast cancer, neoadjuvant chemotherapy, pathological complete response, gene expression classifier, luminal breast cancer, molecular subtypes, treatment de-escalation, external validation
MeSH terms
Clinical Decision-Making, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Mastectomy, Middle Aged, Neoplasm Staging, Predictive Value of Tests, Prognosis, Prospective Studies, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Treatment Outcome, Chemotherapy, Adjuvant, Patient Selection, Neoadjuvant Therapy, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Datasets as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gene Expression–Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-2662
The paper
Edlund, K., Madjar, K., Lebrecht, A., Aktas, B., Pilch, H., Hoffmann, G., Hofmann, M., Kolberg, H.-C., Boehm, D., Battista, M., Seehase, M., Stewen, K., Gebhard, S., Cadenas, C., Marchan, R., Brenner, W., Hasenburg, A., Koelbl, H., Solbach, C., . . . Hengstler, J. G. (2021). Gene Expression–Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-2662

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.